Journal of Bioscience and Bioengineering, Vol.120, No.4, 432-437, 2015
High-yield preparation of recombinant human alpha-thrombin for therapeutic use
In this study, we established stable cell lines producing 1.5 mg/mL recombinant human prothrombin in 400-L fed-batch culture, using CHO DG44 cells as a host cell line. And we also established a recombinant human alpha-thrombin purification process that produces a purified product suitable for use as a biopharmaceutical, by using recombinant ecarin from CHO DG44 cells, achieving a total yield of approximately 27% of prothrombin in culture medium. The establishment of stable cell lines with high expression levels, long-term passage stability and satisfactory scale-up are essential to ensure the stable supply of biopharmaceuticals. Furthermore, biopharmaceuticals must be of high quality to assure safety and effectiveness in target applications. We had previously reported that recombinant human prethrombin-2 expression level in a stable cell line established using the mouse myeloma cells, Sp2/0-Ag14, reached 200 mu g/mL using animal-free materials in 50-L fed-batch culture. However, the productivity was insufficient to completely replace alpha-thrombin in human plasma preparations. By employing CHO DG44 cells as a host cell line, we had established a stable cell line and achieved significant improvements in quality, productivity of recombinant human alpha-thrombin manufacture suitable for use as a biopharmaceutical. (C) 2015, The Society for Biotechnology, Japan. All rights reserved.
Keywords:Recombinant;Human alpha-thrombin;Ecarin;High-yield preparation;Therapeutic use;Biopharmaceuticals